ArticleDermatology and therapy2026

Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study.

Igor Snast et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.